Laurence J Egan

List of Publications by Year
in descending order

57	6,125	159358	182168
papers	citations	30 h-index	51 g-index

58	58	58	8451
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	IKKÎ² Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. Cell, 2004, 118, 285-296.	13.5	2,277
2	The two faces of IKK and NF-Î¹B inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nature Medicine, 2003, 9, 575-581.	15.2	506
3	Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointestinal Endoscopy, 2008, 68, 255-266.	0.5	333
4	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. Journal of Crohn's and Colitis, 2015, 9, 945-965.	0.6	328
5	Inhibition of Interleukin-1-stimulated NF-Î¹B RelA/p65 Phosphorylation by Mesalamine Is Accompanied by Decreased Transcriptional Activity. Journal of Biological Chemistry, 1999, 274, 26448-26453.	1.6	195
6	Gastrointestinal radiation injury: Symptoms, risk factors and mechanisms. World Journal of Gastroenterology, 2013, 19, 185.	1.4	190
7	IÂB-kinaseÂ-dependent NF-ÂB activation provides radioprotection to the intestinal epithelium. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2452-2457.	3.3	185
8	Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine. American Journal of Gastroenterology, 1998, 93, 442-448.	0.2	171
9	Gastroesophageal reflux disease in pregnancy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 793-806.	1.0	147
10	Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis, 2012, 33, 723-731.	1.3	144
11	Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF-Î¹B and MAP kinase pathways and the upregulated expression of interleukin 8. Cellular Microbiology, 2002, 4, 635-648.	1.1	141
12	Upregulation of DNA Methyltransferaseâ€“Mediated Gene Silencing, Anchorage-Independent Growth, and Migration of Colon Cancer Cells by Interleukin-6. Molecular Cancer Research, 2010, 8, 471-481.	1.5	139
13	Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 537-545.	1.3	115
14	Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2. Journal of Cell Science, 2007, 120, 492-501.	1.2	113
15	Gastrointestinal radiation injury: Prevention and treatment. World Journal of Gastroenterology, 2013, 19, 199.	1.4	111
16	Optimising monitoring in the management of Crohn's disease: A physician's perspective. Journal of Crohn's and Colitis, 2013, 7, 653-669.	0.6	96
17	Methotrexate for Inflammatory Bowel Disease: Pharmacology and Preliminary Results. Mayo Clinic Proceedings, 1996, 71, 69-80.	1.4	82
18	Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer. Cancer Immunology Research, 2018, 6, 1426-1441.	1.6	66

#	Article	IF	Citations
19	Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (II). Journal of Crohn's and Colitis, 2014, 8, 19-30.	0.6	61
20	Autophagosomal ÎºBÎ± Degradation Plays a Role in the Long Term Control of Tumor Necrosis Factor-Î±-induced Nuclear Factor-ÎºB (NF-ÎºB) Activity. Journal of Biological Chemistry, 2011, 286, 22886-22893.	1.6	57
21	Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?. Oncotarget, 2016, 7, 60752-60774.	0.8	56
22	Acute Pancreatitis in Patients With CrohnÊ¼s Disease: Clinical Features and Outcomes. Inflammatory Bowel Diseases, 2005, 11, 1080-1084.	0.9	53
23	Budesonide in the treatment of inflammatory bowel disease: The first year of experience in clinical practice. Inflammatory Bowel Diseases, 2006, 12, 29-32.	0.9	49
24	Endoscopic Factors in the Diagnosis of Colorectal Dysplasia in Chronic Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2005, 11, 428-434.	0.9	48
25	Antianoikis Effect of Nuclear Factor-ÎºB through Up-regulated Expression of Osteoprotegerin, BCL-2, and IAP-1. Journal of Biological Chemistry, 2006, 281, 8686-8696.	1.6	48
26	NF-ÂB Signaling: Pros and Cons of Altering NF-ÂB as a Therapeutic Approach. Annals of the New York Academy of Sciences, 2006, 1072, 114-122.	1.8	42
27	New Insights into the Mechanisms of Action of Antiâ€“Tumor Necrosis Factor-Î± Monoclonal Antibodies in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2909-2920.	0.9	42
28	Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis. Epigenetics, 2017, 12, 591-606.	1.3	40
29	Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease. Biomaterials, 2022, 281, 121364.	5.7	37
30	Expression of Epstein-Barr virus-induced gene 3 and other interleukin-12-related molecules by human intestinal epithelium. Immunology, 2004, 112, 437-445.	2.0	36
31	Pharmacogenomics in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 21-28.	2.4	30
32	The AmpliChip CYP450 Test: Principles, Challenges, and Future Clinical Utility in Digestive Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 822-830.	2.4	22
33	Is There a Role for Nuclear Factor ÎºB in Tumor Necrosis Factorâ€Related Apoptosisâ€Inducing Ligand Resistance?. Annals of the New York Academy of Sciences, 2009, 1171, 38-49.	1.8	19
34	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17808-17819.	3.3	18
35	Plasma and Rectal Adenosine in Inflammatory Bowel Disease: Effect of Methotrexate. Inflammatory Bowel Diseases, 1999, 5, 167-173.	0.9	17
36	The intestinal epithelial cell cycle. Current Opinion in Gastroenterology, 2015, 31, 124-129.	1.0	16

#	Article	IF	Citations
37	New Perspectives in Gastric Acid Suppression: Genetic Polymorphisms Predict the Efficacy of Proton Pump Inhibitors. Digestive Diseases, 2000, 18, 58-63.	0.8	12
38	Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: A case study of five patients with treatment-resistant inflammatory bowel disease. Inflammatory Bowel Diseases, 2000, 6, 286-289.	0.9	11
39	Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose) Tj ETQq1 1 0.784314 rgBT /Ove	1.1	9
40	Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. European Journal of Gastroenterology and Hepatology, 2018, 30, 1019-1026.	0.8	9
41	Celiac Disease and T-Cell Lymphoma. New England Journal of Medicine, 1996, 335, 1611-1612.	13.9	8
42	Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2016, 22, 2863-2878.	0.9	8
43	Subtotal colectomy in ulcerative colitisâ€"long term considerations for the rectal stump. World Journal of Gastrointestinal Surgery, 2021, 13, 198-209.	0.8	7
44	Mechanisms of Drug Toxicity or Intolerance. Digestive Diseases, 2011, 29, 172-176.	0.8	6
45	Differential DNA methylation patterns of homeobox genes in proximal and distal colon epithelial cells. Physiological Genomics, 2016, 48, 257-273.	1.0	6
46	Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterology, 2020, 11, 441-447.	0.9	6
47	Drug interactions in gastroenterology: Mechanisms, consequences, and how to avoid. Clinical Gastroenterology and Hepatology, 2004, 2, 725-730.	2.4	4
48	Positioning novel biologic, probiotic, and apheresis therapies for crohnâ€™s disease and ulcerative colitis. Current Gastroenterology Reports, 2005, 7, 485-491.	1.1	4
49	Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2020, 55, 786-794.	0.6	2
50	Allopurinol and 6MP: Steering through the therapeutic obstacle course. Inflammatory Bowel Diseases, 2007, 13, 1312-1313.	0.9	1
51	Endoscopy Capsule Retention in a Young Female with Small Bowel Strictures Secondary to Non-Steroidal Anti-Inflammatory Drugs. Case Reports in Gastroenterology, 2021, 15, 948-953.	0.3	1
52	AZATHIOPRINE DOWNREGULATES TRAIL EXPRESSION IN A T CELL LINE AND IN NORMAL HUMAN PERIPHERAL BLOOD T CELLS. American Journal of Gastroenterology, 2003, 98, S256.	0.2	0
53	A Nudge in the Right Direction: Shaping the Metabolic Fate of Thiopurines for Therapeutic Gain. Clinical Gastroenterology and Hepatology, 2007, 5, 170-171.	2.4	0
54	Taking a closer look at IBD. Gut, 2014, 63, e1-e1.	6.1	0

#	Article	IF	Citations
55	A new hand on the tiller: Taking over the editorship of the Journal of Crohn's and Colitis. Journal of Crohn's and Colitis, 2014, 8, 91-92.	0.6	0
56	Corrigendum to â€˜Optimising monitoring in the management of Crohn's disease: A physician perspectiveâ€™ [Journal of Crohn's and Colitis volume 7 (2013) 653â€“669]. Journal of Crohn's and Colitis, 2014, 8, 441.	0.6	0
57	Ten Years of the Journal of Crohnâ€™s and Colitis. Journal of Crohn's and Colitis, 2017, 11, 1029-1029.	0.6	0